FATE THERAPEUTICS INC (FATE)
2025-03-31 | 2024-09-30 | |||
|---|---|---|---|---|
| Collaboration revenue | 1,629 | 3,074 | ||
| Research and development | 29,136 | 34,650 | ||
| General and administrative | 13,773 | 20,801 | ||
| Total operating expenses | 42,909 | 55,451 | ||
| Loss from operations | -41,280 | -52,377 | ||
| Other income | 43 | 274 | ||
| Interest income | 3,336 | 4,438 | ||
| Change in fair value of stock price appreciation milestones | -280 | 13 | ||
| Total other income | 3,659 | 4,699 | ||
| Net loss | -37,621 | -47,678 | ||
| Unrealized loss on available-for-sale securities, net | -77 | 1,257 | ||
| Comprehensive loss | -37,698 | -46,421 | ||
| Basic eps | -0.32 | -0.4 | ||
| Diluted eps | -0.32 | -0.4 | ||
| Basic average shares | 118,375,540 | 117,769,161 | ||
| Diluted average shares | 118,375,540 | 117,769,161 | ||